A61K 31 - Medicinal preparations containing organic active ingredients

Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2002
11/14/2002	US20020168340 For inhibiting and treating HIV-1 and HIV-2 infections
11/14/2002	US20020168334 Liquid formulations for the prevention and treatment of mucosal diseases and disorders
11/14/2002	US20020168333 Method for improving vascular access in patients with vascular shunts
11/14/2002	US20020168327 Use of lipophilic agent or lipid precursor and/or promoter for treating and/or preventing dandruff by strengthening scalp
11/14/2002	US20020168325 Administering inhibitor of nitric oxide synthase
11/14/2002	US20020166789 Composition for IVF
11/14/2002	DE10213304A1 Topical pharmaceutical composition having carrier system forming lamellar double membrane structure with water, providing good skin barrier permeation and high bioavailability without side-effects
11/14/2002	DE10126198A1 Neue Verwendung von 2-Phenyl-substituierten Imidazotriazinonen New use of 2-phenyl-substituted imidazotriazinones
11/14/2002	DE10123129A1 Deuterierte 3-Piperidinopropiophenone sowie diese Verbindungen enthaltende Arzneimittel Deuterated 3-piperidinopropiophenones and pharmaceutical compositions containing them
11/14/2002	DE10122898A1 Use of 2-phenyl-4-chromanone derivatives to mask bitter or metallic tastes in foods, consumables and oral pharmaceutical products
11/14/2002	DE10122894A1 New pyrazolo(3,4-b)pyridin-3-yl)-5-pyrimidinyl sulfonates, are soluble guanyl cyclase stimulants useful e.g. for treating cardiovascular, thromboembolic or central nervous system diseases
11/14/2002	DE10122523A1 New 1,3-dihydroxybenzo-fused decalactone compounds, are cellular kinase inhibitors and hormone receptor inhibitors, useful as e.g. antitumor, anti-infective, antifungal and antiprotozoal drugs
11/14/2002	DE10122342A1 Verwendung von Isoflavonen in kosmetischen oder dermatologischen Zubereitungen Use of isoflavones in cosmetic or dermatological preparations
11/14/2002	DE10121982A1 Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung Nanoparticles of protein with coupled apolipoprotein E to cross the blood-brain barrier and method for their preparation
11/14/2002	DE10121638A1 Verfahren zur Herstellung von Imidazopyridinen Process for the preparation of imidazopyridines
11/14/2002	DE10121466A1 Ointment for treating dry and inflamed nasal mucosa comprises olive oil, dexpanthenol, an oily carrier and an ointment base
11/14/2002	DE10121002A1 Verwendung von Anthranilsäureamiden als Medikament zur Behandlung von Arrhythmien sowie sie enthaltende pharmazeutische Zubereitungen Use of anthranilamides as a medicament for the treatment of arrhythmias and pharmaceutical compositions containing them
11/14/2002	DE10120610A1 Nasal therapeutic composition in ointment or emulsion form comprises castor oil, lavender oil and naphazoline hydrochloride
11/14/2002	DE10119680A1 Verwendung von Radikalfänger-Verbindungen zur Behandlung und Verhinderung von no-abhängigen Störungen der Mikrozirkulation Use of scavenger compounds for the treatment and prevention of no-dependent disorders of microcirculation
11/14/2002	CA2827671A1 Phosphorus-containing antimicrobial compounds and methods for their use
11/14/2002	CA2484596A1 17-methylene-androstan-3alpha-ol analogs as crh inhibitors
11/14/2002	CA2453223A1 Selective anthranilamide pyridinamides as vegfr-2 and vegfr-3 inhibitors
11/14/2002	CA2449166A1 Combination therapy using anti-egfr antibodies and anti-hormonal agents
11/14/2002	CA2447360A1 Pharmaceutical compositions for preventing or treating th1 and th2 cell related diseases by modulating the th1/th2 ratio.
11/14/2002	CA2447045A1 Method for treatment of tumors using nordihydroguaiaretic acid derivatives
11/14/2002	CA2446926A1 Dermatological formulations
11/14/2002	CA2446838A1 Novel mutation
11/14/2002	CA2446810A1 Epidermal growth factor receptorantisense oligonucleotides
11/14/2002	CA2446795A1 Sulfamide, sulfamate, sulfonamide, urea, amide, alpha, alpha-difluoro amide oxalyl diamide, and heterobicycles fkbp-binding ligands
11/14/2002	CA2446788A1 Compositions and methods for the therapy and diagnosis of prostate cancer
11/14/2002	CA2446735A1 Substituted cyclohexane-1,4-diamine derivatives with an anti-diarrhoea and peripheral analgesic action
11/14/2002	CA2446666A1 Method for detecting progredient chronic dementia, and associated peptides and detection reagents
11/14/2002	CA2446652A1 Treatment of adhd
11/14/2002	CA2446640A1 .beta.-amyloid peptide-binding proteins and polynucleotides encoding the same
11/14/2002	CA2446528A1 Disinfecting and solubilizing steroid compositions
11/14/2002	CA2446458A1 Toll/interleukin-1 receptor adaptor protein (tirap)
11/14/2002	CA2446396A1 N-aroyl cyclic amines
11/14/2002	CA2446372A1 Ectoparasiticidal compositions and methods of their use
11/14/2002	CA2446365A1 Sulfonamides
11/14/2002	CA2446363A1 Potentiation of therapeutic effects of fatty acids
11/14/2002	CA2446351A1 Fused heterocyclic compounds
11/14/2002	CA2446244A1 Cationic antibacterial dentifrice exhibiting superior foaming properties
11/14/2002	CA2446234A1 Alpha-2-adrenergic agonist/fatty acid compositions
11/14/2002	CA2446204A1 Anti-virus agent
11/14/2002	CA2446161A1 Use of an ampa receptor potentiator for the manufacture of a medicament for the treatment of type 2 diabetes
11/14/2002	CA2446120A1 Novel arylheteroalkylamine derivatives
11/14/2002	CA2446099A1 Cephem compounds
11/14/2002	CA2446060A1 Compositions and delivery systems for administration of a local anesthetic agent
11/14/2002	CA2446051A1 Phthalazine derivatives with angiogenesis inhibiting activity
11/14/2002	CA2446036A1 A method for transfection of rna using electrical pulses
11/14/2002	CA2445985A1 Hyaluronic acid containing bioconjugates: targeted delivery of anti-cancer drugs to cancer cells
11/14/2002	CA2445982A1 Sperm-specific cation channel, and uses therefor
11/14/2002	CA2445923A1 Arylsulfonamide ethers, and methods of use thereof
11/14/2002	CA2445766A1 Improved process for preparing zolpidem
11/14/2002	CA2445679A1 Benzazepinone alpha v integrin receptor antagonists
11/14/2002	CA2445634A1 Acne treatment comprising lipoxygenase inhibitors
11/14/2002	CA2445504A1 Methods of treating hyperlipidemia
11/14/2002	CA2445502A1 Method and compositions for treating migraines
11/14/2002	CA2445381A1 Phosphorous containing antimicrobial compounds and methods for their use
11/14/2002	CA2445271A1 Use of castanospermine esters to treat flaviviridae-related diseases
11/14/2002	CA2445146A1 Formation of small crystals
11/14/2002	CA2445065A1 Trimethyl lock based tetrapartate prodrugs
11/14/2002	CA2444718A1 Method of administration of bisphosphonates by inhalation in the treatment or prevention of bone resorption and osteoporosis
11/14/2002	CA2444531A1 Isoquinolinone derivatives as parp inhibitors
11/14/2002	CA2444013A1 Combination of a gelatinase inhibitor and an anti-tumor agent, and uses thereof
11/14/2002	CA2442969A1 Methods for selective immunomodulation using pimecrolimus
11/14/2002	CA2440017A1 Treatment of hpv caused diseases
11/14/2002	CA2385809A1 Alkylamide compounds
11/13/2002	EP1256589A2 Oligomers containing modified pyrimidines
11/13/2002	EP1256585A1 Process fot preparing 9-(2-(diethylphosphonomethoxy)ethyl)-adenine
11/13/2002	EP1256584A1 Process for preparing adefovir dipivoxil
11/13/2002	EP1256583A1 Pyrimidine-4-one derivatives, process for their preparation and pharmaceutical compositions containing them
11/13/2002	EP1256582A1 1h-imidazopyridine derivatives
11/13/2002	EP1256581A1 Preventive or therapeutic agents for gastric or esophageal regurgitation
11/13/2002	EP1256578A1 Thiazole derivatives and their use as cdk inhibitors
11/13/2002	EP1256576A1 Fused imidazolium derivatives
11/13/2002	EP1256575A1 Phenoxyalkylamine derivatives useful as opioid delta receptor agonists
11/13/2002	EP1256353A1 Remedies for sjoegren's syndrome
11/13/2002	EP1256350A1 New toralactone and its derivation and the use of decreasing blood-fat and losing weight
11/13/2002	EP1256349A1 Cell activator
11/13/2002	EP1256348A1 Remedies for hepatitis c
11/13/2002	EP1256347A1 Use of starch for the preparation of an agent for therapeutic treatment
11/13/2002	EP1256346A1 Remedies for external use for allergic skin diseases
11/13/2002	EP1256345A1 Combination therapy for treatment of psychoses
11/13/2002	EP1256344A1 Remedies for endothelin-induced diseases
11/13/2002	EP1256343A1 Flibanserin for the treatment of extrapyramidal movement disorders
11/13/2002	EP1256342A1 Hypoglycemics comprising organic zinc (ii) complexes
11/13/2002	EP1256341A1 Cancer remedy comprising anthranilic acid derivative as active ingredient
11/13/2002	EP1256340A1 Improved transdermal therapeutic system for the treatment of Parkinson's disease
11/13/2002	EP1256339A1 Transdermal therapeutic system for Parkinson's disease inducing high plasma levels of rotigotine
11/13/2002	EP1256336A2 Two-phase gel composition
11/13/2002	EP1256335A1 Use of procyanidine oligomers
11/13/2002	EP1256283A2 Phytopharmaceutical food products
11/13/2002	EP1255870A2 5-hydroxytryptamine transporter gene polymorphisms
11/13/2002	EP1255850A1 AMPLIFICATION OF $i(CYP24) AND USES THEREOF
11/13/2002	EP1255845A2 Modified cytokines for use in cancer therapy
11/13/2002	EP1255840A2 Gene cluster encoding a nystatin polyketide synthase and its manipulation and utility
11/13/2002	EP1255837A2 Il-17 like molecules and uses thereof
11/13/2002	EP1255835A2 Polypeptides and nucleic acids encoding same
11/13/2002	EP1255833A2 Polypeptides and nucleic acids encoding same

1 ... 5651 5652 5653 5654 5655 5656 5657 5658 5659 5660 5661 5662 5663 5664 5665 5666 5667 5668 5669 5670 5671 ... 7860